Precision medicine company completes independent audit validating security controls protecting sensitive healthcare data
CHICAGO, IL – April 23, 2026 – Prenosis®, a biology-based technology company advancing integrated diagnostics and therapeutics for acute care, today announced it has successfully completed its SOC 2 Type II audit. The independent audit, conducted by Advantage Partners and supported by Vanta’s trust management platform, validates that Prenosis has implemented effective security controls to protect the sensitive clinical and patient data central to its Immunix® platform and Sepsis ImmunoScore®.
SOC 2 compliance is governed by the American Institute of Certified Public Accountants (AICPA) and requires an independent auditor to evaluate whether an organization’s policies, procedures, and controls are designed and operating effectively to safeguard customer data.
“Earning and maintaining the trust of our healthcare partners is fundamental to everything we do at Prenosis. SOC 2 certification is an important milestone in that commitment, and one step in our ongoing work to continuously strengthen the security posture our partners and patients depend on,” said Brian Bray, VP of Technology at Prenosis.
Protecting critical healthcare information is a continuous priority at Prenosis. As the company deepens its work with health systems, device and therapeutics partners, and channel partners, SOC 2 compliance is one of many steps in its ongoing commitment to data security and protection. The SOC 2 report was issued on March 27, 2026, and Prenosis will recertify annually as part of its security program.
About Prenosis, Inc.
Prenosis® is a biology-based technology company redefining the standard of care for critical conditions. We believe healthcare should not follow a one-size-fits-all model. Instead, our mission is to tailor healthcare to each patient’s biology through the creation and delivery of integrated diagnostics and therapeutics. We use deep data and AI to build tools that augment clinical diagnosis of critical conditions based on each patient’s unique biological profile. Unlike other AI-driven diagnostics, we go further by developing therapies that help providers deliver personalized care. Our Immunix® platform powers the development of a variety of AI-based diagnostics, including Sepsis ImmunoScore®, the first FDA-authorized AI diagnostic tool for sepsis. At Prenosis, we see people differently. For more information, visit us on LinkedIn.